Skip to main content
Ross Donehower, MD, Oncology, Lutherville, MD

Ross C Donehower MD

Oncology•Lutherville, MD

Professor of Oncology, Professor of Medicine, Johns Hopkins University School of Medicine; Director, Medical Oncology/Hematogy Fellowship Training Program, Director, Division of Medical Oncology

Join to View Full Profile

  • 10803 Falls RoadPavilion Iii Ste 1500Lutherville, MD 21093

  • Phone+1 410-583-2970

  • Fax+1 410-583-2980

Dr. Donehower is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Donehower's Full ProfileAlready have an account?

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1980
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1974 - 1976
  • University of Minnesota Medical School
    University of Minnesota Medical SchoolClass of 1974

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1979 - 2026
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Excellence in Teaching Award American Society of Clinical Oncology, 2017
  • America's Top Doctors Castle Connolly, 2002-2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Johns Hopkins University Hematology Oncology Fellowship
    Johns Hopkins University Hematology Oncology FellowshipApril 30th, 2017

Grant Support

  • Clinical Oncology Research Career Development ProgramNational Cancer Institute1997–2007
  • Phase I Trial/Pharmacokinetis Of Tas 103 Solid In TumorsNational Center For Research Resources2000–2002
  • Trial Of Bryostatin 1 Given As Continuous Infusion In Cancer PatientsNational Center For Research Resources1998–2002
  • Phase I Dose Escalation, Safety, Tolerability Of Tas 103National Center For Research Resources1997–2002
  • Phase I Trials Of Anticancer AgentsNational Cancer Institute1998–2000
  • Phase II Pharm Study--Flavopiradol (Nsc 649890) In Colorectal CancerNational Center For Research Resources1999
  • Phase II Trials Of New Anticancer AgentsNational Cancer Institute1994–1998
  • Phase I Clinical Trial Of Anticancer AgentsNational Cancer Institute1995–1997
  • Pharmacokinetic Studies Of Anticancer AgentstheDivision Of Cancer Treatment1994–1995
  • Navelbine Bioavailability In Solid Tumors And LymphomaNational Center For Research Resources1992–1993
  • 7u85 Mesylate Intravenous Administration Daily For Five DaysNational Center For Research Resources1992–1993
  • Phase I And Pharmacokinetic Studies Of Anticancer AgentsDivision Of Cancer Treatment1990–1993
  • Bioavailability Of Piritrexim Isethionate In Advanced Cancer PatientsNational Center For Research Resources1992

Professional Memberships

External Links

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Ross Donehower, Dr. Ross Donehower, MD, Dr. R Donehower, Dr. Ross C Donehower